Are you seeing patients suffering from NASH?
Then you need to join us in Barcelona!
Who should attend?
This interactive workshop is specifically designed for the needs of all healthcare professionals that encounter patients with NASH in their clinical practice.
Why should you attend?
After attending this workshop, you will have practical knowledge on:
- Multidisciplinary clinical management of patients with NASH
- Epidemiology, risk factors and diagnosis of NASH
- Comorbidities in NASH
- Future treatment options for NASH
- Current guidelines used for diagnosing and treating NASH
Expert Medical Events is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The European NASH Workshop is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of the population worldwide. In 10% of patients, NAFLD progresses into NASH, a fibrogenic phenotype that can potentially result in cirrhosis, liver failure and the formation of hepatocellular carcinoma.
Although NAFLD is globally the most prevalent chronic liver disease and the second leading indication for liver transplant evaluation in the US, knowledge concerning the molecular mechanisms favouring the development and progression of the disease are not fully understood. Current understanding supports the hypothesis that environmental and genetic factors equally influence disease progression.
Considering the far-reaching societal and economic burden caused by NAFLD, it is of utmost importance to identify and subsequently implement guidelines to stage, diagnose and treat the disease efficiently.
In particular, there is an unmet need for approved drugs that allow the pharmacological treatment of (pre-)cirrhotic NASH. By using surrogate endpoints, the drug approval process for NASH is accelerated and approved agents are expected to enter the market in the near future.
This workshop aims to train clinicians on current and future treatment options. We specifically aim to provide practical guidance to secondary stakeholders, such as endocrinologists, diabetologists, cardiologists and general practitioners, on how to manage NAFLD/NASH.
This workshop aims to:
- Review current and future treatment options and discuss challenges associated with the implementation of certain treatments
- Discuss gaps in current diagnosis and management guidelines and provide
- guidance on how the management of patients suffering from NASH can be improved
- Raise awareness for NASH among important stakeholders such as endocrinologists, diabetologists and cardiologists
- Accelerate the implementation of new policies by stimulating cross-disciplinary discussions